Intrexon and Ziopharm enter exclusive license agreement

Intrexon Corp. (NYSE: XON) and Ziopharm Oncology Inc. (Nasdaq: ZIOP) entered an exclusive licensing agreement with the University of Texas MD Anderson Cancer Center to develop non-viral adoptive cellular cancer immunotherapies. Shares of Intrexon leaped $9.50 to $37.87 while Ziopharm stock surged $3.11 to $8.85.